SPRY2 and prostate neoplasm: We propose targeting cholesterol bioavailability using statins or tumoral cholesterol uptake using ITX5061, a clinically safe SRB1 antagonist, as two strategies to sensitise prostate tumours with SPRY2 deficiency or HER2 activation to the standard‐of‐care androgen deprivation therapy.